@inproceedings{inproceedings, title  = {{DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation}},

 url = {{}},

 year = {{2022}},

 month = {{1}},

 author = {{Niazi T and McBride SM and Williams S and Davis ID and Stockler MR and Martin AJ and Bracken K and Roncolato F and Horvath L and Sengupta S and Martin J et al}},

 volume = {{40}},

 journal = {{JOURNAL OF CLINICAL ONCOLOGY}},

 issue = {{16}},

 note = {{Accessed on 2024/12/22}}}